Evidence map›Paper›PMID 39037913›Full record

ArticleeLife2024

Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity.

Christin Krause, Jan H Britsemmer, Miriam Bernecker, Anna Molenaar, Natalie Taege, Nuria Lopez-Alcantara, Cathleen Geißler, Meike Kaehler, Katharina Iben, Anna Judycka and 9 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Epigenetic Mechanisms in Heart Diseases.Reviews in cardiovascular medicine · 2025
    Review
  9. Review
  10. Review
  11. Emerging role of exosomal-microRNA in obesity.Current opinion in physiology · 2025
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Christin KrauseInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.ORCID https://orcid.org/0000-0001-8703-0023
Jan H BritsemmerInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.
Miriam BerneckerGerman Center for Diabetes Research (DZD), Munich, Germany.ORCID https://orcid.org/0009-0004-8324-7515
Anna MolenaarGerman Center for Diabetes Research (DZD), Munich, Germany.
Natalie TaegeInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.
Nuria Lopez-AlcantaraCenter of Brain, Behaviour and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
Cathleen GeißlerInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.
Meike KaehlerInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Katharina IbenInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.
Anna JudyckaInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.
Jonas WagnerDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Stefan WolterDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Oliver MannDepartment of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Paul PflugerGerman Center for Diabetes Research (DZD), Munich, Germany.
Ingolf CascorbiInstitute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0002-2182-9534
Hendrik LehnertCenter of Brain, Behaviour and Metabolism (CBBM), University of Lübeck, Lübeck, Germany.
Kerstin StemmerGerman Center for Diabetes Research (DZD), Munich, Germany.
Sonja C SchrieverGerman Center for Diabetes Research (DZD), Munich, Germany.ORCID https://orcid.org/0000-0001-5461-3214
Henriette KirchnerInstitute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, Lübeck, Germany.ORCID https://orcid.org/0000-0002-7887-247X

Funding

Deutsche Forschungsgemeinschaft CRC-TR296Deutsche Forschungsgemeinschaft GRK-1957Deutsche Forschungsgemeinschaft KI 1887/2-1Deutsche Forschungsgemeinschaft KI 1887/2-2Deutsche Forschungsgemeinschaft KI 1887/3-1Deutsches Zentrum für Diabetesforschung 82DZD09D1GEuropean Research Council 101002247
6 · The paper itself

Abstract

Background: The development of obesity-associated comorbidities such as type 2 diabetes (T2D) and hepatic steatosis has been linked to selected microRNAs in individual studies; however, an unbiased genome-wide approach to map T2D induced changes in the miRNAs landscape in human liver samples, and a subsequent robust identification and validation of target genes are still missing. Methods: Liver biopsies from age- and gender-matched obese individuals with (n=20) or without (n=20) T2D were used for microRNA microarray analysis. The candidate microRNA and target genes were validated in 85 human liver samples, and subsequently mechanistically characterized in hepatic cells as well as by dietary interventions and hepatic overexpression in mice. Results: Here, we present the human hepatic microRNA transcriptome of type 2 diabetes in liver biopsies and use a novel seed prediction tool to robustly identify microRNA target genes, which were then validated in a unique cohort of 85 human livers. Subsequent mouse studies identified a distinct signature of T2D-associated miRNAs, partly conserved in both species. Of those, human-murine miR-182-5 p was the most associated with whole-body glucose homeostasis and hepatic lipid metabolism. Its target gene Conclusions: By mapping the hepatic miRNA-transcriptome of type 2 diabetic obese subjects, validating conserved miRNAs in diet-induced mice, and establishing a novel miRNA prediction tool, we provide a robust and unique resource that will pave the way for future studies in the field. As proof of concept, we revealed that the repression of Funding: This work was supported by research funding from the Deutsche Forschungsgemeinschaft (KI 1887/2-1, KI 1887/2-2, KI 1887/3-1 and CRC-TR296), the European Research Council (ERC, CoG Yoyo LepReSens no. 101002247; PTP), the Helmholtz Association (Initiative and Networking Fund International Helmholtz Research School for Diabetes; MB) and the German Center for Diabetes Research (DZD Next Grant 82DZD09D1G).

Indexed as

Diabetes Mellitus, Type 2LiverMicroRNAsObesityTranscriptomeAnimalsFatty LiverFemaleGene Expression ProfilingHumansMaleMiceMice, Inbred C57BLMiddle AgedMicroRNAsMirn182 microRNA, humanMirn182 microRNA, mousehumanlivermedicinemicroRNAmouseobesitytype 2 diabetes

Identifiers

PMID39037913
PMCPMC11262792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.